Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01439880
Registration number
NCT01439880
Ethics application status
Date submitted
22/09/2011
Date registered
23/09/2011
Date last updated
21/09/2022
Titles & IDs
Public title
Open Label Study of Long Term Evaluation Against LDL-C Trial
Query!
Scientific title
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
Query!
Secondary ID [1]
0
0
2011-001915-29
Query!
Secondary ID [2]
0
0
20110110
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
OSLER
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Evolocumab
Other interventions - Standard of care
Active comparator: Standard of Care - Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product \[all-IP\] period.
Experimental: Evolocumab + SOC - Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
Treatment: Other: Evolocumab
Administered by subcutaneous injection
Other interventions: Standard of care
Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [1]
0
0
Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.03, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.
Query!
Timepoint [1]
0
0
52 weeks in the SOC-controlled period and up to 4 years in the All-IP period; actual median duration of treatment in the All-IP period was 46.9 months.
Query!
Secondary outcome [1]
0
0
Low-density Lipoprotein Cholesterol (LDL-C) Level at Week 24 and Week 52
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline of parent study and extension study weeks 24 and 52
Query!
Secondary outcome [2]
0
0
Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Level at Week 24 and Week 52
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline of parent study and extension study weeks 24 and 52
Query!
Secondary outcome [3]
0
0
Apolipoprotein B Level at Week 24 and Week 52
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline of parent study and extension study weeks 24 and 52
Query!
Secondary outcome [4]
0
0
Total Cholesterol/HDL-C Ratio at Week 24 and Week 52
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline of parent study and extension study weeks 24 and 52
Query!
Secondary outcome [5]
0
0
Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24 and Week 52
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline of parent study and extension study weeks 24 and 52
Query!
Eligibility
Key inclusion criteria
* Complete a qualifying evolocumab (AMG 145) parent study protocol, including: 20101154 (NCT01375777), 20101155 (NCT01380730), 20090158 (NCT01375751), 20090159 (NCT01375764), and 20110231 (NCT01652703)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Experienced a treatment-related serious adverse event that led to investigational product (IP) discontinuation in the parent study
* Have an unstable medical condition, in the judgment of the investigator
* Known sensitivity to any of the products to be administered during dosing
* Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/10/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/06/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1324
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Research Site - Maroubra
Query!
Recruitment hospital [3]
0
0
Research Site - Sydney
Query!
Recruitment hospital [4]
0
0
Research Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
2015 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2035 - Maroubra
Query!
Recruitment postcode(s) [3]
0
0
2022 - Sydney
Query!
Recruitment postcode(s) [4]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maine
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Montana
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nevada
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Dakota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oklahoma
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Pennsylvania
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Dakota
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Anthée
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Bruxelles
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Gozee
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Gribomont
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Halen
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Ham
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Linkebeek
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Ukkel
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
British Columbia
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Newfoundland and Labrador
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Ontario
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Quebec
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Brno
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Olomouc
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Praha 2
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Praha 4
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Slany
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Svitavy
Query!
Country [50]
0
0
Czechia
Query!
State/province [50]
0
0
Usti nad Orlici
Query!
Country [51]
0
0
Czechia
Query!
State/province [51]
0
0
Znojmo
Query!
Country [52]
0
0
Denmark
Query!
State/province [52]
0
0
Aalborg
Query!
Country [53]
0
0
Denmark
Query!
State/province [53]
0
0
Ballerup
Query!
Country [54]
0
0
Denmark
Query!
State/province [54]
0
0
Vejle
Query!
Country [55]
0
0
Finland
Query!
State/province [55]
0
0
Helsinki
Query!
Country [56]
0
0
Finland
Query!
State/province [56]
0
0
OYS
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Berlin
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Köln
Query!
Country [59]
0
0
Hong Kong
Query!
State/province [59]
0
0
New Territories
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Budapest
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Debrecen
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Dunaujvaros
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Gyula
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Kecskemet
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Komarom
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Szolnok
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Zalaegerszeg
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Aichi
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Fukui
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Fukuoka
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Gunma
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Hyogo
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Ibaraki
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Ishikawa
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Kagawa
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Kochi
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Kyoto
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Nagano
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Osaka
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Saitama
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Tokyo
Query!
Country [82]
0
0
Netherlands
Query!
State/province [82]
0
0
Amsterdam
Query!
Country [83]
0
0
Netherlands
Query!
State/province [83]
0
0
Hoorn
Query!
Country [84]
0
0
Netherlands
Query!
State/province [84]
0
0
Utrecht
Query!
Country [85]
0
0
Norway
Query!
State/province [85]
0
0
Oslo
Query!
Country [86]
0
0
Singapore
Query!
State/province [86]
0
0
Singapore
Query!
Country [87]
0
0
South Africa
Query!
State/province [87]
0
0
Gauteng
Query!
Country [88]
0
0
South Africa
Query!
State/province [88]
0
0
Western Cape
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Andalucía
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Aragón
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Cataluña
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Madrid
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Göteborg
Query!
Country [94]
0
0
Sweden
Query!
State/province [94]
0
0
Lund
Query!
Country [95]
0
0
Sweden
Query!
State/province [95]
0
0
Stockholm
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01439880
Query!
Trial related presentations / publications
Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 Jun 1;2(6):598-607. doi: 10.1001/jamacardio.2017.0747. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS; OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14;129(2):234-43. doi: 10.1161/CIRCULATIONAHA.113.007012. Epub 2013 Nov 19. Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16. Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1448-1457. doi: 10.1016/j.jacl.2017.09.003. Epub 2017 Sep 22. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 Oct 29;74(17):2132-2146. doi: 10.1016/j.jacc.2019.08.1024. Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31. Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2. Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug;16(4):538-543. doi: 10.1016/j.jacl.2022.05.069. Epub 2022 Jun 6. Hirayama A, Yamashita S, Ruzza A, Inomata H, Cyrille M, Lu C, Hamer AW, Yoshida M, Kiyosue A, Teramoto T. Long-Term Treatment With Evolocumab Among Japanese Patients - Final Report of the OSLER Open-Label Extension Studies. Circ J. 2019 Apr 25;83(5):971-977. doi: 10.1253/circj.CJ-19-0139. Epub 2019 Mar 29. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/80/NCT01439880/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/80/NCT01439880/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01439880
Download to PDF